NCCGAnnualMeeting_KCASBio_2025 June 25 - June 26

KCAS Bio is happy to announce our participation in the 13th edition of the Antibody Industrial Symposium (AIS), taking place in Tours, France. As a premier event in the antibody and therapeutic development sector, AIS offers a unique platform for scientific exchange, collaboration, and innovation. KCAS Bio’s Expertise…

TAKEAWAYS FROM AAPS NBC 2025 Blogs
Read article TAKEAWAYS FROM AAPS NBC 2025

KCAS Bio participated in the AAPS National Biotechnology Conference (NBC), held from May 4 to May 7, 2025, in Boston. It was a productive event that allowed us to connect with sponsors, exchange ideas with peers, and present our latest work in bioanalytical science. Our experts…

QuantitativeAssayForAnInvestigationalAnti-MalarialMonoclonalantibodyDrugCandidate_KCASBio Posters & Papers
Read article Development and Optimization of a Quantitative Assay for an Investigational Anti-Malarial Monoclonal Antibody Drug Candidate in Human Whole Blood Using Volumetric Absorptive Microsampling (VAMS)

Discover in this poster presented by Jessica Phan at WRIB 2025 on the “Development and Optimization of a Quantitative Assay for an Investigational Anti-Malarial Monoclonal Antibody Drug Candidate in Human Whole Blood Using Volumetric Absorptive Microsampling (VAMS)”. Quantitative Assay for an Investigational Anti-Malarial Monoclonal Antibody Drug Candidate |…

Cutting-Edge PK and Immunogenicity Strategies for Next-Generation ADCs, ARCs, and Conjugated Biotherapeutics Webinars
View webinar Cutting-Edge PK and Immunogenicity Strategies for Next-Generation ADCs, ARCs, and Conjugated Biotherapeutics

As the field of biotherapeutics rapidly evolves, the development of advanced conjugated therapies such as Antibody-Drug Conjugates (ADCs), Antibody-RNA Conjugates (ARCs), siRNA/oligos, and antibody-peptide conjugates has gained significant momentum. These next-generation therapeutics offer promising efficacy and safety profiles for treating various conditions, including cancer, rare diseases, and in vaccine development.

ADC ANALYSIS – FREQUENTLY ASKED QUESTIONS BLOG Blogs
Read article ADC Analysis – Frequently Asked Questions

ADCs represent a promising class of targeted therapies, and understanding the intricacies of their analysis is crucial for their successful development. In this blog, we address common questions to guide you through the various considerations involved in ADC research and testing. We will cover key topics related to the…

Refining Method Development & Validation Testing for Antibody Drug Conjugate Payloads Blogs
Read article Refining Method Development & Validation Testing for Antibody Drug Conjugate Payloads

Antibody drug conjugates (ADCs) are important targeted therapies in oncology. These are complex moieties consisting of a cell-targeting antibody combined with an active payload through a chemical linker. Key Components to Monitor in PK Studies Two significant components to monitor for PK studies are the (1) intact antibody drug conjugate…

KCAS-podcast-thumb_TWB-084 Podcasts
Listen to podcast Podcast (The Weekly Bioanalysis) Eps #84: “Small Molecule LC-MS Development and Evolving Approaches to ADC Payloads”

In episode 84 of “The Weekly Bioanalysis”, our special guest, Bryan Parmentier, joins Dom and John to discuss his background and current role at KCAS Bio, offering insights into the field of small molecule method development. He delves into the typical challenges encountered when working with LC-MS analytes, and how…

PBSS San Diego December 10 - December 10

KCAS Bio is excited to sponsor the upcoming Pharmaceutical & BioScience Society (PBSS) workshop “Antibody-Drug Conjugates from Discovery to Development: Chemistry, Engineering, Characterization, CMC, PK/Tox, Clinical Design and Intellectual Property,” on December 10th from 8:45am – 5:30pm PST in San Diego, California at the Hyatt Regency – La Jolla. Showcasing…

KCAS-blog-thumb_2024-ADCsHybridTech Blogs
Read article Supporting ADC Analysis with Hybrid Analytical Services

In the complex and dynamic bioanalytical landscape of antibody-drug conjugate (ADC) services, where often time is critical and every research dollar counts, hybrid technology is quickly emerging as a game-changer. Hybrid offers a spectrum of advantages that redefine traditional approaches to bioanalytical ADC drug development. At the forefront of these…

KCAS-blog-thumb_2024-01B_JPM-ADCs Blogs
Read article Innovations in ADCs at 2024 J.P. Morgan Conference

If you are part of the Biotech/Pharma community, you may be familiar with the (J.P. Morgan) JPM Healthcare Conference that takes place annually in January and typically in San Francisco. This was the 42nd Annual JPM Healthcare Conference and it is the world’s largest healthcare symposium. This year the mood…

KCAS-podcast-thumb_TWB-069 Podcasts
Listen to podcast Podcast Eps #69: “The Evolving world of Antibody-Drug Conjugates & How KCAS Can Help”

Starting with a description of Antibody Drug Conjugates (or ADCs, for short), Dom and John dive into this field of the industry and discuss the ways these services have changed over time and even how they’ve changed recently. They review the role of ADCs in meeting some of…